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The fragile X syndrome is the most frequent cause of inherited mental retardation. The molecular mechanism 
of the disorder is based on the expansion of a CGG repeat in the 5' UTR of the FMR1 gene in the majority of 
fragile X patients. The instability of this CGG repeat containing region is not restricted to the CGG repeat 
itself but expands to the flanking region as well. We describe four unrelated fragile X patients that are mosaic 
for both a full mutation and a small deletion in the CGG repeat containing region. Sequence analysis of the 
regions surrounding the deletions showed that both the (CGG)n repeat and some flanking sequences were 
missing in all four patients. The 5' breakpoints of the deletions were found to be located between 75-53 bp 
proximal to the CGG repeat. This suggests the presence of a hot spot region for deletions in the CGG repeat 
region of the FMR1 gene and emphasizes the instability of this region in the presence of an expanded 
CGG repeat.
INTRODUCTION
The fragile X syndrome is the most common inherited form 
of mental retardation (I) and the disorder is associated with 
the expression of a fragile site at Xq27,3. Besides mental 
impairment, the patients are characterized by typical morpholo­
gical features such as large, prominent ears, elongated face 
with mandibular prognathism and macroorchidism (2). The 
incidence of fragile X syndrome is estimated to be approxi­
mately 1 in 1250 males and Í in 2500 females (for review 
see 3).
In the majority of the patients, the molecular mechanism of 
the disorder is based on an unstable (CGG)n trinucleotide 
repeat in the 5' UTR of the FMR1 gene (4-7). In the normal 
population this trinucleotide repeat is polymorphic, varying 
between 6 and 52 repeat units, and is stable upon transmission 
(7). Premutation alleles, ranging from 50-200 repeats, exhibit 
instability, usually resulting in increases in repeat number in 
the offspring when compared to the parents. Premutations are 
not associated with a clinical phenotype and are found in 
female carriers and normal transmitting males. During or after 
passage through female meiosis, a premutation can expand to 
a full mutation of over 200 repeats resulting in méthylation of 
the CGG repeat and the CpG island 250 bp proximal to the 
CGG repeat (5,8-10). This méthylation is associated with 
repression of FMR1 transcription, thereby resulting in the 
severe reduction of the level of FMRJ protein leading to the 
fragile X phenotype (11,12). Although the function of the 
FMR1 protein is not yet fully understood, evidence is accumu­
lating that the protein plays a role in RNA metabolism. Two
motifs have been identified that are present in RNA binding 
proteins; a RGG box and a KH domain (13,14).
Transmission of an expanded CGG repeat mostly results in 
increase in repeat length, although occassionally, regression of 
the CGG repeat has been reported as well. Reduction of a 
premutation to a smaller premutation has been detected (6.7,15- 
17) as well as reduction of a premutation to a repeat length 
within the normal range (18). Decrease from a full mutation 
to a premutation has been reported only once (15), whereas 
the reverse mutation, from full mutation to a normal allele has 
not yet been described. This is in contrast to the CTG repeat 
in myotonic dystrophy, in which a number of independent 
reverse mutations have already been described (19-21).
Several deletions in the FMR1 gene resulting in the fragile 
X syndrome are now known. Two large deletions of 2,5 Mb 
(22) and 3 Mb (23) have been described including the entire 
FMR1 gene plus flanking sequences. In a third patient a 250 
kb deletion resulted in the absence of the FMRl gene associated 
CpG island and the first five exons of the gene (24), whereas 
in a fourth patient - 10 0  kb, including the first eight exons and 
upstream sequences, were missing (25). Recently a small 
deletion of 1.6 kb immediately 5' of the CGG repeat was 
detected, removing regulatory sequences of the gene. This 
deletion resulted in four affected males within a fragile X 
family (26).
The instability of the CGG repeat is not only seen between 
generations, but it can also be seen within one individual. 
Patients with a full mutation display a variety of repeat lengths,
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visible as a smear in Southern blot analysis. In addition, -20% 
of the affected males are mosaic for both a full mutation and 
a premutation allele (5,7,11,15).
In this paper we describe four unrelated fragile X patients 
that are mosaic for a full mutation in the majority of their 
lymphocytes and a deletion of the CGG repeat and flanking 
sequences in -5-10% of their blood lymphocytes. Sequence 
analysis of the deletion junctions revealed that all 5' breakpoints 
are located within 30 bp of each other. This emphasizes the 
instability of the CGG repeat region of FMRL
RESULTS
We studied the length of the CGG repeat and the méthylation 
pattern of the CpG island proximal of the FMR1 gene using 
Southern blot analysis. In normal males and females digestion 
of DNA with EcoRl results in a 5.2 kb fragment. The majority 
of fragile X males exhibit a smear of over 5.8 kb, due to 
expansion of the CGG repeat to over 200 repeats. In four male 
patients, digestion with EcoRl not only resulted in this smear 
but in addition a fragment slightly smaller than the normal 5.2 
kb band was found (data not shown). These novel fragments 
were estimated to be derived from —5—10% of the cells in 
patients 1, 2 and 4 and 15% in patient 3. Double digestion of 
DNA of normal males with EcoRl and the méthylation sensitive 
enzyme Eagl leads to a 2.8 kb fragment (Fig. 1, lanes 6 and 
9). In females both the 2.8 kb fragment and the methylated 
5.2 kb fragment are detected, due to normal X chromosome 
inactivation (Fig. 1, lanes 7 and 8). In fragile X males the 
smear of over 5.8 kb remains due to méthylation of the Eagl 
site. However, in the four male patients we detected both this 
smear as well as a smaller fragment (Fig. 1, lanes 1, 3, 5, 10). 
These fragments varied in size between 2.7 kb in patient 1 
(lane 1) to 2.2 kb in patient 3 (lane 5), again indicating the 
presence of deletions that varied from 150-600 bp, all falling 
within the EcoRl—Eagl 2.8 kb fragment. The Eagl restriction
site could clearly be digested, which implies the absence of 
hypermethylation of the novel iragment. DNA derived only 
from the mothers of patient 1 and 2 was also subjected to 
Southern blot analysis (Fig. 1, lanes 2 and 4, respectively). 
Both females were earners of a premutation and did not have 
the smaller fragment present in their sons. This indicates that 
the deletions in the patients were derived from a ele novo event 
In order to determine the exact junction of the four deletions 
we PCR amplified the region surrounding the CGG repeat, 
The deletion in the Eagl-EcoRl  fragment was only present 
in a low percentage of their cells. Therefore, in order to get a 
sufficient amount of PCR product, we performed two cycles
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Figure 1. Southern blot analysis of the four patients. DNA was digested with 
EcoR\—Eag\ and following electrophoresis, fragments were blotted on filters 
and hybridized with pP2. Lanes 1, 3, 5 and 10 represent patients 1, 2, 3 and 
4 respectively. Lane 2: mother of patient 1 ; lane 4: mother of patient 2; lanes 
6 and 9: control male; lanes 7 and 8: control female. The normal length of 
the fragments are indicated.
Figure 2. Schematic representation, not drawn to scale, of the deletions found 
thus far in the CGG region. The position of the primers in the pE5.1 sequence 
are indicated (32) as triangles, WT: wild type sequence; ATG; startcodon. 
Patients (Pat.) 1-4 are described in this paper; XTY26 and Pat. 24 were 
described by Kremer et al.Q.1) and Meijer et ai (26), respectively.
Table 1. Junction sequences of seven deletions in the CGG repeat region, 
Patients 1-4 are described in this paper; deletion 24 and XTY26 were repeated 
previously (26,27)
Patient deletion breakpoint®
5' 3'
Patient 1 CCGACGGCGAgçgcgggcgg-------- t t t c t t c t  tgGTGTCGGCGG
Patient 2 C G G T G G A G G G ccacctctga-------- ccgcagcccaCCTCTCGGGG
Patient 3 GCCTCTGAGCaggcggcggg-------- gggccgaaatGGCGCTAAGT
Patient 4 **** ***** ***** **** 
GCCTCTGAGCgggcggcggg-------- cccgcagcccACCTCTCGGG
Pat. 24 TTACACTTGGaggggtataa-^------ crcqqcgqcggCGGCGGCGGC
XTY26 5' GGCGAGCGCGqcrcgqcqacqq------ acaacaacacGGCGGCGGCGG
XTY26 3' CGGCGGCGGCtgggcctcgagqgcCCGCAGCCCAC
@The wild Lype sequence is shown. The deleted sequences are indicated by 
lower case letters. Short regions of homology at the deletion termini are 
underlined. The asterisks denote complementary regions. The Chi-like element 
is indicated in bold italics. Pat. 24 and XTY26 were described by Meijer 
et a i  (26) and Kremer et a i  (27) respectively.
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of amplification standardly. After a Centricon-100 purification, 
the PCR products were sequenced using the same primers as 
were used for amplification. A schematic representation of the 
deletion breakpoints of the four patients described are shown 
in Figure 2. This figure also includes the deletion described 
by Meijer et a l  (26; pat. 24) and Kremer et a l  (32, XTY26). 
The exact sequences of the junctions of all deletions are shown 
in Table 1.
DISCUSSION
The instability of the expanded CGG repeat in the FMRl gene 
is a well known phenomenon. Transmission of a premutation 
to the offspring can result in increase and decrease of the 
CGG repeat, whereas increase to a full mutation only occurs 
after transmission by a female (6,7,28). The variation of repeat 
length is not only found between generations but is also present 
within individual fragile X patients and is called somatic 
instability or mosaicism. Two different types of mosaicism 
have been observed. Firstly, there is the wide range of repeat 
lengths of the full mutation, visible as a smear on Southern 
blot analysis (7,29,30). Secondly, 20% of the fragile X patients 
are mosaic for a premutation allele in addition to the full 
mutation (7,11,15). Mosaicism is established in early fetal life. 
Identical patterns of mosaicism were demonstrated in different 
fetal tissues of monozygotic twins (30) and a 13 week old 
fetus (31). In vitro studies on proliferation of single fibroblasts 
from adults resulted in several clones, each carrying only one 
repeat length (29). This indicates that once mosaicism is 
established early in development it remains stable during life.
In this paper we describe a third kind of mosaicism; in four 
unrelated fragile X males we detected both a full mutation 
and a deletion of the CGG repeat and flanking sequences. The 
deletions in patients 1 and 3 encompasses the first ATG of 
FMRl. Therefore these patients will not produce a functional 
protein. The other two patients may have FMRl mRNA and 
protein expression but this could not be tested. However, this 
may be irrelevant, for it has already been shown that mosaic 
males, with both a full mutation and a premutation, have some 
mRNA expression but do not have a significantly different 
clinical phenotype than patients with a full mutation only 
(11,15).
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Figure 3. Possible stemHoop DNA structure formed at the deletion junction 
of patient 4. Single DNA strand from position 2642 to 2795 (32) is shown. 
Alignment of the complementary sequences at the junction results in the 
formation of a stem-loop. The cleavage site is indicated by the arrow.
The deletions reported in this paper are not the first deletions 
known in the region flanking the CGG repeat. In 1991, Kremer 
et cil (27) sequenced the 1 kb Pstl fragment, that was found 
to contain the unstable CGG repeat. This sequence was 
obtained from a YAC (XTY26) that was subcloned from a 
hybrid cell line (X.3000.1) expressing a fragile X chromosome. 
Southern blot analysis had shown that this cell line contained 
-350 triplets. However, only 43 CGGs were detected in the 
YAC, indicating that a large part of the repeat had been deleted 
during cloning. Sequence analysis of this region in DNA of 
both fragile X patients and unaffected individuals performed 
independently by Fu et a l  (7) revealed that in the YAC 
some of the CGG flanking sequences were lacking as well. 
Remarkably, the 5' endpoint of the deletion in the YAC, at 
position 2671 of the pE5.1 fragment, is also located within 
the 35 bp interval in which the 5' endpoints of the other four 
deletions are found (Fig. 2; 32).
Recently, a deletion in the CGG region has been described 
in a fragile X family (26). The 3' endpoint of this 1.6 kb 
deletion was located within the CGG repeat and the deletion 
was assumed to be caused by an expanded, unstable CGG 
repeat. Previously, four large deletions, spanning 2.5 Mb, 3 
Mb, 250 kb and 100 kb respectively, in the fragile X gene 
have been described (22-25). The CGG repeats of the mothers 
of these patients were in the normal range suggesting that 
these deletions were not caused by an unstable CGG repeat. 
The four deletions described in this paper appear to be directly 
derived from an expanded, unstable CGG repeat; all four 
patients expressed a full mutation smear on Southern blot 
analysis besides the deletion fragment (Fig. 1 ).
An intriguing question remains: when did the deletion take 
place? In 1993, Reyniers et a l  (33) showed the presence of a 
premutation and not a full mutation in sperm of patients with 
a full mutation in their blood cells. From this they postulated 
two hypotheses on the possible timing of the CGG repeat 
amplification. The first model assumed expansion during 
meiosis of the oocyte, resulting in the presence of a full 
mutation in all somatic cells. In sperm cells this full mutation 
regressed to a premutation and due to a selection mechanism 
only cells with a premutation will proliferate. In the second 
model a premutation expands to a full mutation during postzyg- 
otic proliferation of the somatic cells, after the separation of 
the germ line (day 5-6 post conception). Recent breeding 
studies with fragile X knock out mice demonstrated that Fmrl 
gene expression is not required for gametogenesis (34). In 
addition, Meijer et a l  (26) showed that the 1.6 kb deletion 
resulted in the absence of FMR1 mRNA in the affected males 
of the family and that this deletion was originally derived 
from a male with a progeny of five children. This confirms 
that the expression of FMR1 is not required for spermatogen­
esis, thus excluding the presence of a selection mechanism in 
sperm. The second model therefore seems more likely.
The deletions of the four patients described in this paper 
could originate from either a premutation or a full mutation. 
In the first case the premutation allele expands, resulting in a 
full mutation in the offspring. However, due to a certain error, 
in a few cells instead of expansion a deletion takes place. In 
the latter case, the premutation allele of the mother expands 
to a full mutation. This full mutation, which is somatically 
much more unstable than premutations, later, during subsequent 
proliferation and development of the zygote, results in a 
deletion in a low percentage of the cells. It is possible that all
48 Human Molecular Genetics, 1995, Vol. 4, No. 1
premutations found in mosaic patients are the result of regres­
sion of a full mutation indicating that reduction of the CGG 
repeat is a more frequent event than expected. Female carriers 
of a full mutation can have children with either both a full 
and a premutation or a full mutation alone. In these mosaics 
the premutation may well be caused by a deletion of a large 
number of CGGs in the full mutation of the mother. A similar 
deletion mechanism could have resulted in a patient described 
by Van den Ouweland et al. (35). This patient had, in addition 
to a full mutation, two alleles within the normal range. The 
repeat length of these normal alleles, 21 and 33 respectively, 
did not correspond to the mother’s normal allele of 29 repeats. 
The sequences flanking the repeat were found to be normal 
suggesting that regression within the mother’s expanded CGG 
repeat resulted in the two normal alleles present in this patient. 
In most cases the deletion that causes the reduction from full 
mutation to premutation will be restricted to the CGG repeat 
meaning that on Southern blot analysis either a normal or a 
premutated fragment will be detected. These deletions will not 
be noticed in diagnostic screening, resulting in an underestima­
tion of the total percentage of deletion events. Occasionally, 
the deletion will also involve sequences flanking the CGG 
repeat, resulting in the four deletions described in this paper, 
now estimated to be below \%. It should be noted that these 
latter deletions will not be detected if the diagnostic analysis 
is performed by PCR using primers immediately flanking 
the repeat.
Regression of a full mutation to a premutation would involve 
two mechanisms: the reduction in number of CGG repeats and 
déméthylation. Both the premutations found in mosaic patients 
and the deletions described in this paper are unmethylated 
fragments (Fig. 1). Déméthylation may be explained by the 
fact that méthylation of the CpG island is an active process, 
maintained by the presence of a full mutation. Disappearance 
of the full mutation would then result in passive déméthylation. 
Méthylation being an active mechanism might explain the 
occurrence of unmethylated full mutations (36). The possibility 
that déméthylation is an active process in itself, causing the 
deletion by, for instance, nicking, can not be excluded.
Several studies on the mechanism of deletions have shown 
that -40%  of the large deletions in human disorders are Hanked 
by very short direct repeats of 2-6  bp (37-39). It is proposed 
that these short repeats slip and mispair during replication, 
resulting in the formation of a loop between the two repeats 
(37,38). Subsequent excision of this loop removes both the 
sequences between the repeats as well as one of the repeats. 
Of the seven deletions in the CGG region of FMRÌ now 
known five have such a short region of homology (Table 1). 
Patient 3 and the deletion described by Meijer et a i  (26) have 
a GG flanking the deletion. The deletion of XTY26 at the 3' 
site of the repeat is flanked by a CG and in patient 2 the 
deletion is flanked by a CC. It should be noted however, that 
the CGG region of FMR1 is very C-G rich and that both GG, 
GC and CC are present rather often in this region. It can 
therefore not be excluded that the presence of the 2 bp repeats 
represents a chance occurrence. The deletion at the 5' site of 
the CGG repeat of XTY26 is a better example of this slippage 
mispairing mechanism. This deletion is flanked by a sequence 
repeat of 11 bp (Table 1).
Another mechanism may account for the deletion in patient
4. This deletion is flanked by a short inverted repeat; 9 out of 
10 bp are complementary (Table 1). These sequences can
align together in a quasi-palindromic manner, resulting in the 
formation and subsequent excision of the loop, as previously
described (40,41; Fig. 3).
Neither of the two mechanisms can explain the close vicinity 
of the 5' endpoint of the different deletions. Recently Jeffreys 
et a i  (42) demonstrated that both gain and loss of repeat units 
in a minisatellite mainly occurred at one end of the repeat. 
They postulated the presence of a specific mutation initiator 
element adjacent to the repeat that would cause the instability 
by inducing a double strand break. Such an element could be 
a Chi element, a short sequence that is often located in the 
vicinity of breakpoints. Chi or Chi-like elements are thought 
to play a major part in recombination processes (43) and may 
also be involved in replication slippage (44). At position 2626, 
immediately 5' of the breakpoint of patient 2, a Chi-like 
sequence is present (GGTGGAGG; Table 1) and could cause 
a DNA break. Subsequent misrepair of this break, possibly 
caused by the presence of a large CGG repeat, would then 
result in a deletion.
Our results that only the 5' and not the 3' breakpoints of 
the deletions are located within a hotspot, correlate well 
with the previous findings of Kunst and Warren (45). They 
demonstrated that expansion of the CGG repeat occurs at the 
3' end of the repeat. Both studies thus indicate that variability 
of the CGG repeat is mainly present at the 3' site, suggesting 
that the replication of this region goes in one direction.
In conclusion we have described a hotspot of deletions -70 
bp upstream of the (CGG)n repeat. These findings may help 
in future unravelling of the mechanism of the CGG repeat 
expansion.
MATERIALS AND METHODS
Patients
Patient 1 has a Prader—Willi like phenotype and was previously described by 
de Vries et a i  (46). The three other patients have the classical M artin -B e ll  
phenotype.
Southern blot analysis
Genomic DNA was isolated from blood leukocytes according to standard 
procedures (47). Seven jig DNA was digested to completion with £cy;RI and 
Eagh electrophoresed on a 0.7% agarose gel and transferred to Hybond N +  
blotting membrane. Probes StB12,3 (5) or pP2, a 1 kb Pstl fragment derived 
from pE5.1 which identifies the (CGG)n repeat and the preceding CpG island
(48), were used after labelling by the random oligonucleotide priming method
(49). After overnight hybridization the filters were washed to 0 .1XSSC, 0.1% 
SDS at 65°C prior to exposure to X-ray film.
PCR and sequencing analysis
Amplification was performed using 200 ng of genomic DNA in a total volume 
of 50 |il in the presence of 0.2 mM each of dATP, dCTP and dTTP, 0.05 mM 
dGTP, 0.15 mM 7-deaza-dGTP, 10 mM T r is -C l  pH 8.3, 50 mM KCl, 10% 
DMSO, 1 mM MgCli, 2.5 U Taq polymerase (BRL) and I jiM of each primer. 
The reactions were first denatured for 5 min at 95°C, followed by 30 cycles 
of 2 min at 95°C, 2 min at 61°C and 2 min at 72°C. A final extension o f  10 
min was carried out at 72°C. In order to get enough product to use for 
sequencing, a sample of 2.5 |il of the PCR product was additionally amplified 
another 30 cycles using the same conditions. Products were analysed on a 1% 
agarose gel, stained with ethidium bromide. After a Centricon-100 purification 
(Amicon), the PCR products of the second amplification were directly 
sequenced using the BRL cycle sequencing kit. The primers used for the PCR 
reactions and the sequencing protocols as well as their position in the pE5.1 
sequence are indicated (between brackets) (32):
#013
#014
#019
#203
#213
5'-CGCGTCTGTCTTTCGACCCG (2409-2429) 
5 #-TAGGCGCTAGGGCCTCTCGG (3073-3093) 
S'-TTCACAGCCCTCGCCCAGAACAG (3408-3430) 
S'-GCGCTCAGCTCCGTTTCGTTT (2597-2619, ref.27)
5 '-CTCCATCTTCTCTTCGCCCTGCTAG (2816-2842, ref.27)
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